Vivo Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
43
- Investments
-
354
- Portfolio
-
59
- Exits
-
226
Vivo Capital General Information
Company Description
Founded in 1996, Vivo Capital is a venture capital firm based in Palo Alto, California. The firm seeks to invest globally in biopharmaceuticals, specialty pharmaceuticals, medical devices, and other subsectors of the healthcare and life sciences sectors. This firm is a Registered Investment Adviser (RIA).
Business Details
Website
www.vivocapital.comYear Founded
Investor Status
Trade Association
Primary Investor Type
Other Investor Types
Corporate Office
- 192 Lytton Avenue
- Palo Alto, CA 94301
- United States
Vivo Capital Investments (354)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Createrna | 13-Nov-2026 | Later Stage VC | Pharmaceuticals | Generating Revenue | ||
| Mentari Therapeutics | 06-Nov-2026 | Drug Discovery | Generating Revenue | |||
| Mentari Therapeutics | 06-Nov-2026 | Drug Discovery | Generating Revenue | |||
| Albus Laboratories | 04-Nov-2026 | Distributors (Healthcare) | Generating Revenue | |||
| Celgenyx | 29-Sep-2026 | Drug Discovery | Generating Revenue | |||
| Serán BioScience | 29-Sep-2026 | BPO/Outsource Services | Generating Revenue | |||
| Korsana Biosciences | 07-Sep-2026 | Drug Discovery | Pre-Clinical Trials | |||
| Expedition Therapeutics | 05-Aug-2026 | Biotechnology | Clinical Trials - Phase 2 | |||
| Caldera Therapeutics | 29-Jul-2026 | PIPE | Drug Discovery | Clinical Trials - Phase 1 | ||
| Celta Ingenieros | 28-Jul-2026 | Buyout/LBO | Distributors (Healthcare) | Generating Revenue |
Vivo Capital Exits (226)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Bolt Biotherapeutics | 23-Oct-2026 | Merger/Acquisition | |
| ADARx Pharmaceuticals | 25-Sep-2026 | ||
| Silence Therapeutics | 11-Aug-2026 | ||
| BlossomHill Therapeutics | 06-Aug-2026 | ||
| ViOptix | 15-Jul-2026 | ||
| Ajax Therapeutics | 13-Jun-2026 | ||
| Scientia Vascular | 12-Jun-2026 | ||
| HanchorBio | 29-May-2026 | ||
| Soleno Therapeutics | 18-May-2026 | Merger/Acquisition | |
| Clene | 06-May-2026 | Public Investment 2nd Offering |
Vivo Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Vivo Capital Investments by Industry, Year, and Region
Vivo Capital Co-Investors (215)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| RA Capital Management | 5 |
|
|
||
| Johnson & Johnson JJDC |
|
|
|||
| LAV (Lilly Asia Fund) |
|
|
|||
| Novo Holdings |
|
|
|||
| SR One |
|
|
Vivo Capital Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vivo Ventures | Sao Paulo, Brazil | 2022 | |
| Vivo Equity Investment Management | Beijing, China |
Vivo Capital FAQs
-
What is Vivo Capital?
Founded in 1996, Vivo Capital is a venture capital firm based in Palo Alto, California.
-
When was Vivo Capital founded?
Vivo Capital was founded in 1996.
-
Where is Vivo Capital headquartered?
Vivo Capital is headquartered in Palo Alto, CA.
-
What is Vivo Capital's total asset value?
Vivo Capital has around in total assets under management.
-
How many investments has Vivo Capital made?
Vivo Capital has made 354 investments.
-
What has Vivo Capital invested in?
Vivo Capital has made numerous investments in companies like Createrna, Mentari Therapeutics, and Albus Laboratories within the Pharmaceuticals, Drug Discovery, and Distributors (Healthcare) industries.
-
What has Vivo Capital invested in recently?
Vivo Capital's latest investment was on 13-Nov-2026 in Createrna, a company within the Pharmaceuticals industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process